- Home
- RIGL vs ITRN Comparison
RIGL vs ITRN Comparison
Compare RIGL & ITRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ITRN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electronic Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 1.0B |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ITRN |
|---|---|---|
| Price | $51.03 | $52.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $63.00 | ★ $74.50 |
| AVG Volume (30 Days) | ★ 187.5K | 67.3K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 3.75% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | $16.43 |
| Revenue Next Year | $21.95 | $5.43 |
| P/E Ratio | $38.83 | ★ $16.85 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $35.22 |
| 52 Week High | $52.24 | $68.30 |
Technical Indicators
Market Signals| Indicator | RIGL | ITRN |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 54.58 |
| Support Level | $44.83 | $50.17 |
| Resistance Level | N/A | $53.04 |
| Average True Range (ATR) | 1.53 | 1.20 |
| MACD | 0.30 | 0.29 |
| Stochastic Oscillator | 75.79 | 73.14 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About ITRN Ituran Location and Control Ltd.
Ituran Location and Control Ltd is a provider of location-based services. The company operates in two segments, namely Telematics services and Telematics products. The Telematics services segment consists of regionally-based stolen vehicle recovery (SVR) services, fleet management services, and value-added services comprised of personal locater services and concierge services. The Telematics product segment consists of short and medium-range two-way machine-to-machine wireless communications products that are used for various applications, including automatic vehicle location and automatic vehicle identification. Its geographical segments include Israel, Brazil, and Others. The company derives maximum revenue from Israel.